Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Burkitt Lymphoma --- radiotherapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cancer has been a patient-specific and difficult-to-treat disease for decades, resulting in more deaths since 1900 than all other diseases except cardiovascular diseases. As societies around the world continue to shift towards an aging population, the social and economic burden created by cancer will only rise in the coming decades, necessitating continued improvement in our cancer therapies. Remarkably, in the late 1800s, bone surgeon William Coley serendipitously discovered that bacteria could be administered to patients as an effective (and sometimes toxic) form of cancer therapy known as "Coley's Toxins". His discoveries unknowingly led to two fields of cancer therapy that have been in development for decades and are now leading to significant improvements in therapy for cancer patients: immune-based and toxin-based therapies for cancer. Articles included here discuss the discoveries that emerged from Coley's Toxins that enable us to harness the immune system and microbial toxins to combat cancers, as oncology shifts from a field dominated by chemotherapy for most of the 20th century to biologic therapies that will dominate the 21st century.

Medicine --- immunotoxin --- ribotoxin --- α-sarcin --- RNase T1 --- furin --- intracellular trafficking --- colorectal cancer --- botulinum toxin --- botulinum neurotoxin --- cancer --- cancer cells --- neuropathic pain --- post-surgical pain --- parotid gland --- submaxillary gland --- gustatory hyperhidrosis --- sialocele --- parotid fistula --- immunotherapy --- vaccine --- immune checkpoint inhibitors --- adoptive cell therapy --- cytokine therapy --- Coley's Toxins --- glioblastoma --- drug discovery --- cytotoxic necrotizing factor type 1 --- protein purification --- recombinant protein production --- shiga toxins --- Gb3/CD77 --- apoptosis --- ER stress --- autophagy --- Burkitt lymphoma --- immunotoxin --- ribotoxin --- α-sarcin --- RNase T1 --- furin --- intracellular trafficking --- colorectal cancer --- botulinum toxin --- botulinum neurotoxin --- cancer --- cancer cells --- neuropathic pain --- post-surgical pain --- parotid gland --- submaxillary gland --- gustatory hyperhidrosis --- sialocele --- parotid fistula --- immunotherapy --- vaccine --- immune checkpoint inhibitors --- adoptive cell therapy --- cytokine therapy --- Coley's Toxins --- glioblastoma --- drug discovery --- cytotoxic necrotizing factor type 1 --- protein purification --- recombinant protein production --- shiga toxins --- Gb3/CD77 --- apoptosis --- ER stress --- autophagy --- Burkitt lymphoma

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cancer has been a patient-specific and difficult-to-treat disease for decades, resulting in more deaths since 1900 than all other diseases except cardiovascular diseases. As societies around the world continue to shift towards an aging population, the social and economic burden created by cancer will only rise in the coming decades, necessitating continued improvement in our cancer therapies. Remarkably, in the late 1800s, bone surgeon William Coley serendipitously discovered that bacteria could be administered to patients as an effective (and sometimes toxic) form of cancer therapy known as "Coley's Toxins". His discoveries unknowingly led to two fields of cancer therapy that have been in development for decades and are now leading to significant improvements in therapy for cancer patients: immune-based and toxin-based therapies for cancer. Articles included here discuss the discoveries that emerged from Coley's Toxins that enable us to harness the immune system and microbial toxins to combat cancers, as oncology shifts from a field dominated by chemotherapy for most of the 20th century to biologic therapies that will dominate the 21st century.

Medicine --- immunotoxin --- ribotoxin --- α-sarcin --- RNase T1 --- furin --- intracellular trafficking --- colorectal cancer --- botulinum toxin --- botulinum neurotoxin --- cancer --- cancer cells --- neuropathic pain --- post-surgical pain --- parotid gland --- submaxillary gland --- gustatory hyperhidrosis --- sialocele --- parotid fistula --- immunotherapy --- vaccine --- immune checkpoint inhibitors --- adoptive cell therapy --- cytokine therapy --- Coley’s Toxins --- glioblastoma --- drug discovery --- cytotoxic necrotizing factor type 1 --- protein purification --- recombinant protein production --- shiga toxins --- Gb3/CD77 --- apoptosis --- ER stress --- autophagy --- Burkitt lymphoma --- n/a --- Coley's Toxins

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This volume aims to bring together efforts with a patient-oriented focus from physicians to diagnostics and clinical implications of the disease as mostly seen in the equatorial African setting. However, the chapters cover the breadth of studies on Burkitt’s lymphoma with some clues for the potential future of Burkitt’s lymphoma research that can have therapeutic benefits for patients.    This text explore a range of topics associated with Burkitt’s lymphoma, including molecular biology, diagnosis, its association with AIDS and Malaria, immune responses, therapeutic approaches and a unique view from the bedside. This volume is comprehensive and unique and represents the most up-to-date clinical and research activities on Burkitt’s lymphoma.

Burkitt''s lymphoma. --- Epstein-Barr Virus Infections --- Lymphoma, B-Cell --- Lymphoma, Non-Hodgkin --- Tumor Virus Infections --- Herpesviridae Infections --- Lymphoma --- Lymphoproliferative Disorders --- DNA Virus Infections --- Virus Diseases --- Neoplasms, Experimental --- Neoplasms --- Neoplasms by Histologic Type --- Immunoproliferative Disorders --- Diseases --- Lymphatic Diseases --- Hemic and Lymphatic Diseases --- Immune System Diseases --- Burkitt Lymphoma --- Medicine --- Health & Biological Sciences --- Oncology --- Burkitt's lymphoma. --- African lymphoma --- Burkitt tumor --- Burkitt's African lymphoma --- Burkitt's tumor --- Medicine. --- Cancer research. --- Pharmacology. --- Biomedicine. --- Cancer Research. --- Pharmacology/Toxicology. --- B cells --- Epstein-Barr virus diseases --- Tumors --- Oncology. --- Toxicology. --- Chemicals --- Pharmacology --- Poisoning --- Poisons --- Toxicology --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Drugs --- Pharmacy --- Cancer research --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

MicroRNAs are the best representatives of the non-coding part of the genome and their functions are mostly linked to their target genes. During the process of carcinogenesis, both dysregulation of microRNAs and their target genes can explain the development of the disease. However, most of the target genes of microRNAs have not yet been elucidated. In this book, we add new information related to the functions of microRNAs in various tumors and their associated targetome.

Medicine --- Oncology --- miR526b --- miR655 --- breast cancer --- angiogenesis --- lymphangiogenesis --- EP4 --- PI3K/Akt --- microRNA-361 --- EMT --- tumor microenvironment --- cancer diagnosis --- cancer treatment --- Bladder cancer --- microRNA --- genetic marker --- progression --- ccRCC --- prognostic biomarker --- miRNA --- transcription factor --- interplay --- microRNAs --- exosomes --- liquid biopsy --- metastasis --- cancer --- liquid biopsies --- tumor --- SNAIL (SNAI1) transcription factor --- epithelial to mesenchymal transition (EMT) --- long non-coding RNAs (lncRNAs) --- circular RNAs --- viral miRNAs --- EBV --- HHV-8 --- HPV --- HCV --- HBV --- MCPyV --- glioblastoma --- MGMT --- survival --- radiotherapy --- chemotherapy --- temozolomide --- translational medicine --- oncomiRNA --- post-transcriptional regulation --- immune regulation --- adrenocortical carcinoma --- micro RNA --- non-coding RNA --- thyroid carcinoma --- radioactive iodine --- drug resistance --- prognosis --- Burkitt lymphoma --- miR-378a-3p --- cell growth --- pancreatic cancer --- radioresistance --- personalized medicine --- biomarker --- target --- miR526b --- miR655 --- breast cancer --- angiogenesis --- lymphangiogenesis --- EP4 --- PI3K/Akt --- microRNA-361 --- EMT --- tumor microenvironment --- cancer diagnosis --- cancer treatment --- Bladder cancer --- microRNA --- genetic marker --- progression --- ccRCC --- prognostic biomarker --- miRNA --- transcription factor --- interplay --- microRNAs --- exosomes --- liquid biopsy --- metastasis --- cancer --- liquid biopsies --- tumor --- SNAIL (SNAI1) transcription factor --- epithelial to mesenchymal transition (EMT) --- long non-coding RNAs (lncRNAs) --- circular RNAs --- viral miRNAs --- EBV --- HHV-8 --- HPV --- HCV --- HBV --- MCPyV --- glioblastoma --- MGMT --- survival --- radiotherapy --- chemotherapy --- temozolomide --- translational medicine --- oncomiRNA --- post-transcriptional regulation --- immune regulation --- adrenocortical carcinoma --- micro RNA --- non-coding RNA --- thyroid carcinoma --- radioactive iodine --- drug resistance --- prognosis --- Burkitt lymphoma --- miR-378a-3p --- cell growth --- pancreatic cancer --- radioresistance --- personalized medicine --- biomarker --- target